07:20 AM EDT, 10/10/2025 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) has agreed to acquire biotechnology company Orbital Therapeutics for $1.5 billion in cash, the companies said Friday.
The deal includes the experimental OTX-201 CAR T-cell therapy designed to reprogram cells in-vivo with potential applications for autoimmune diseases.